Patients with active , moderate RA were enrolled in a randomised , multicentre , double-blind , placebo-controlled , dose-escalation trial of intravenous MOR103 ( 0.3 , 1.0 or 1.5 mg/kg ) once a week for 4weeks , with follow-up to 16weeks .